2015

Away we go...

Japan deal done.  Check. 

AP26113 gets FDA Breakthrough therapy Designation.  Check

Financing in place for at least next nine months.  Check. 

Billionaires going long on Ariad. Check.

God Molecule coming any day now.  Check

2015 is going to be fun.  I can't wait.

Merry Christmas everyone. 

TC

please send this letter to Kendra Adams at IR

Kendra.Adams@ariad.com

Dear Ms. Adams,

The year is now coming to a close, and  many are wondering if Dr. Berger will be honoring his commitment to announce the new molecule in 2014.  Could you kindly advise if Ariad will be respecting this comittment to shareholders?

Best regards,  and thank you.

[Your Name]

ASH Flash 3: Strong Evidence of Superior Efficacy and Durability of Response with Ponatinib vs. Bosutinib

From American Society for Hematology conference:

Paper No: 3154
Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison
Moshe Yair Levy, MD, Baylor University Med Center

CONCLUSIONS:  Our indirect comparison using a variety of surrogate measures provides strong evidence of superior efficacy and durability of response with ponatinib vs. bosutinib in 3L CP-CML patients; the higher proportion of ponatinib patients continuing on therapy and the longer duration of therapy also suggest patients experience better overall response and tolerability outcomes with ponatinib vs. bosutinib.  Based on the surrogate measures of patient benefit- risk examined in this analysis, ponatinib appears to provide a net overall benefit vs. bosutinib in 3L CP-CML patients.:  

ASH Flash 2: Initial Data Show Responses are Maintained After Dose Reduction

From the American Society of Hematology:

3135 Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: 

Conclusions: Ponatinib continues to exhibit deep and durable responses in heavily pretreated pts with longer follow-up, particularly CP-CML. A dose reduction strategy was implemented in response to the observation of ATEs.  Initial data show responses are maintained after dose reduction; longer follow-up is needed to understand impact on safety.  A dose-ranging trial of ponatinib in refractory CML to evaluate benefit/risk is being planned.

ASH Flash 1: Ponatinib Doses as low as 10 mg were still associated with disease control overall.

From the American Society of Hematology:

3153 High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II

Conclusions:

BARD enables a detailed exploration of dose-response relationships in CP-CML.  In newly diagnosed patients, ponatinibdoses as low as 15 mg induced more rapid decreases in BCR-ABL levels than 400 mg imatinib.  Consistent with the possibility that sequential treatment with TKIs increases the degree of BCR-ABL independence, the magnitude of BCR-ABL decreases induced by ponatinib in heavily pretreated patients was reduced compared with newly diagnosed patients. Nonetheless, ponatinib doses as low as 10 mg were still associated with disease control overall.  These analyses will help inform the design of future studies aimed at optimizing the benefit/risk of ponatinib treatment for patients with CML.